News
Sep 4, 2024
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs through Clinical Development
Read MoreMay 6, 2024
ArsenalBio Announces Presentation of Four Abstracts at ASGCT Annual Meeting Highlighting New Mechanisms for Leveraging CAR T Cells to Address Solid Tumor Cancers
Read MoreApr 30, 2024
Arsenal Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of AB-2100 in Development as a Treatment for Clear-cell Renal Cell Carcinoma
Read MoreApr 5, 2024
Arsenal Biosciences Announces Presentation of Four Abstracts at AACR Annual Meeting Highlighting New CAR T-Focused Research
Read MoreJan 2, 2024
Arsenal Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Read MoreMay 16, 2023
ArsenalBio Announces Presentations Highlighting Preclinical Data on AB-1015 and AB-2100 at ASGCT Annual Meeting
Read MoreApr 14, 2023